CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
dabrafenib +1 moredrug
Likely dose
dabrafenib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01723202
NCT01723202Phase 2Completed
CompareCT.gov

A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma

Bhavana Konda·interventional·Posted Nov 7, 2012·Updated Aug 24, 2025

In Brief

A Phase 2 clinical trial evaluating dabrafenib and trametinib for Follicular Thyroid Cancer and 3 related conditions. Completed, enrolled 53 participants across 5 sites.

Detailed Summary

This randomized phase II trial studies how well dabrafenib works with or without trametinib in treating patients with recurrent thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether dabrafenib is more effective when given with or without trametinib in treating thyroid cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer
CountriesUnited States
CollaboratorsNational Comprehensive Cancer Network

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 7, 2012
Enrollment StartNov 7, 2012
Primary CompletionApr 15, 2022
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 13.7 years ago

Interventions

dabrafenibdrug

150 mg orally twice daily given orally

trametinibdrug

150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally